In a call with @ludwinski she mentioned Pfizer are looking to trial Lorlatinib very very soon in some centers.
Lorlatinib has had some amazing initial results:
Lorlatinib has increased activity towards ALK mutants prevalent in neuroblastoma examined in both in vitro kinase assays and cell-based experiments examining ALK mutations. In contrast to crizotinib, single agent administration of lorlatinib causes a dramatic tumor inhibition in mouse models of high-risk neuroblastoma. Taken together, the research groups show that lorlatinib is a potent inhibitor of crizotinib-resistant ALK mutations, and highlight an important new treatment option for neuroblastoma patients.
I was wondering if there are any more details about where this trial will run and who will have access?
This also raises the question about ALK testing in frontline, at the moment SIOPEN do not dictate ALK testing and only some COG centers that participate in the biology study will test.